A Phase 2 clinical trial involving gonadorelin changed status as of September 25, 2026. The study, titled "Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer," is registered as NCT06369610.
According to the trial record, the study is currently listed as active but not recruiting. This means enrollment has closed, but participants may still be in follow up or treatment phases.
The trial is designed to evaluate a de-escalated hormone therapy approach combined with radiation therapy in prostate cancer patients, stratified by risk category. Gonadorelin is included as part of the hormone therapy regimen under investigation in this Phase 2 setting.
No results have been posted for this trial as of the update date. The current status reflects only the recruitment and progress stage of the study, not any outcome data or efficacy findings.
Gonadorelin is an approved compound with established regulatory status. This trial update pertains specifically to its investigational use in this de-escalated hormone therapy protocol for prostate cancer treatment alongside radiation therapy.
Readers interested in learning more about gonadorelin, including its approved uses and general profile, can consult the compound overview for additional context.